A Budget-Impact (BI) Analysis of Tazemetostat for the Treatment of 3L+Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States

被引：0
|
作者：
Watson, Lucy [1 ]
Harrison, Owen [1 ]
Cockrum, Paul [2 ]
Veazey, Kylee [2 ]
Gaugris, Sabine [1 ]
Kim, George [3 ]
机构：
[1] FIECON, St Albans, England
[2] Ipsen, Cambridge, MA USA
[3] Mayo Clin Florida, Div Hematol & Oncol, Jacksonville, FL USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
IBCL; tazemetostat; relapsed/refractory follicular lymphoma; R/R FL; budget impact; cost saving;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IBCL-461
引用
收藏
页码：S498 / S499
页数：2
相关论文
共 13 条
  • [1] Tazemetostat in Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Propensity Score-Matched Analysis of E7438-G000-101 Trial Outcomes
    Proudman, David
    Gupta, Deepshekhar
    Nellesen, Dave
    Wong, Alex
    Yang, Jay
    Kamp, Beth
    Mamlouk, Khalid
    Cheson, Bruce
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S403 - S403
  • [2] A Cost-Effectiveness Analysis of Mosunetuzumab for Treatment of Third-or Higher-Line Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States (US)
    Matasar, Matthew
    Alvarez, Javier Sanchez
    Parise, Helene
    Zuk, Eric
    Di Maio, Danilo
    Shapouri, Sheila
    Kim, Eunice
    Lin, Shih-Wen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S455 - S456
  • [3] Primary Analysis of the Phase 2 ELARA Trial: Tisagenlecleucel Efficacy and Safety in Adult Patients with Relapsed/Refractory Follicular Lymphoma (r/r FL)
    Schuster, Stephen J.
    Dickinson, Michael
    Dreyling, Martin
    Martinez-Lopez, Joaquin
    Kolstad, Arne
    Butler, Jason
    Ghosh, Monalisa
    Popplewell, Leslie
    Chavez, Julio C.
    Bachy, Emmanuel
    Kato, Koji
    Harigae, Hideo
    Kersten, Marie Jose
    Andreadis, Charalambos
    Riedell, Peter
    Zia, Aiesha
    Morisse, Mony Chenda
    Fowler, Nathan Hale
    Thieblemont, Catherine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S403 - S404
  • [4] Clinical Outcomes of Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated With Tisagenlecleucel: Phase 2 ELARA 3-Year Follow-Up
    Schuster, Stephen J.
    Fowler, Nathan Hale
    Dickinson, Michael
    Martinez-Lopez, Joaquin
    Kolstad, Arne
    Butler, Jason
    Ghosh, Monalisa
    Popplewell, Leslie
    Chavez, Julio C.
    Bachy, Emmanuel
    Kato, Koji
    Harigae, Hideo
    Kersten, Marie Jose
    Andreadis, Charalambos
    Riedell, Peter A.
    Ho, P. Joy
    Perez-Simon, Jose Antonio
    Chen, Andy I.
    Nastoupil, Loretta J.
    von Tresckow, Bastian
    Ferreri, Andres Jose Maria
    Teshima, Takanori
    Patten, Piers E. M.
    McGuirk, Joseph P.
    Petzer, Andreas L.
    Offner, Fritz
    Viardot, Andreas
    Zinzani, Pier Luigi
    Malladi, Ram
    Zia, Aiesha
    Awasthi, Rakesh
    Paule, Ines
    Germano, Davide
    Ramos, Roberto
    Hsu, Pei
    Thieblemont, Catherine
    Dreyling, Martin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S495 - S496
  • [5] inMIND: A Phase 3 Study of Tafasitamab Plus Lenalidomide and Rituximab Versus Placebo Plus Lenalidomide and Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)
    Sehn, Laurie H.
    Hubel, Kai
    Luminari, Stefano
    Salar, Antonio
    Wahlin, Bjorn E.
    Gopal, Ajay K.
    Bonnet, Christophe
    Paneesha, Shankara
    Trneny, Marek
    Mashegu, Hafsat
    Lihou, Christine F.
    Cheng, Lulu
    Scholz, Christian W.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S385 - S386
  • [6] Subcutaneous Epcoritamab With Rituximab plus Lenalidomide (R2) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Update from Phase 1/2 Trial
    Falchi, Lorenzo
    Leppa, Sirpa
    Wahlin, Bjorn E.
    Nijland, Marcel
    Christensen, Jacob Haaber
    De Vos, Sven
    Holte, Harald
    Linton, Kim M.
    Abbas, Aqeel
    Wang, Liwei
    Dinh, Minh
    Elliott, Brian
    Belada, David
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S392 - S392
  • [7] Primary Efficacy and Safety Analysis of a Global Phase II Study of Zandelisib Administered by Intermittent Dosing (ID) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): The TIDAL Study
    Phillips, Tycel
    Jurczak, Wojciech
    Ribrag, Vincent
    Linton, Kim
    Collin, Graham P.
    Lopez-Jimenez, Javier
    Reddy, Nishitha
    Mengarelli, Andrea
    Musuraca, Gerardo
    Sheehy, Oonagh
    Xu, Weiming
    Azoulay, Michel
    Ghalie, Richard G.
    Zinzani, Pier Luigi
    Zelenetz, Andrew D.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S387 - S388
  • [8] Efficacy, Safety, and Patient-Reported Outcomes (PROs) of Treatments for Relapsed/Refractory Follicular Lymphoma (R/R FL) in the Third-Line or Later (3L+) Setting: A Systematic Literature Review (SLR)
    Ma, Qiufei
    Xu, Yingxin
    Kaur, Mandeep
    Soni, Deepali
    Srivastava, Rajni
    Meng, Yang
    Quek, Ruben G. W.
    Mohamed, Hesham
    Ambati, Srikanth
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S406 - S406
  • [9] inMIND: A Phase 3 Study of Tafasitamab plus Lenalidomide Add-On to Rituximab vs Placebo plus Lenalidomide Add-On to Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)
    Sehn, Laurie H.
    Scholz, Christian W.
    Luminari, Stefano
    Salar, Antonio
    Wahlin, Bjorn E.
    Gopal, Ajay K.
    Bonnet, Christophe
    Trneny, Marek
    Paneesha, Shankara
    Manzke, Oliver
    Seguy, Francis
    Li, Di
    Huebel, Kai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S402 - S402
  • [10] Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States
    Matasar, Matthew
    Alvarez, Javier Sanchez
    Parise, Helene
    Zuk, Eric
    Di Maio, Danilo
    Shapouri, Sheila
    Kim, Eunice
    Lin, Shih-Wen
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 766 - 776
12